Eledon Pharmaceuticals, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. This is an annual report, not a standalone fourth-quarter report. The company was formerly Novus Therapeutics and changed its name to Eledon in January 2021.
Business context
Eledon is a clinical-stage biopharmaceutical company with no approved products and no product-sales revenue. Its strategy changed materially in 2020: after its legacy acute otitis media program failed to meet its Phase 2a primary efficacy endpoints, the company suspended development of its ENT assets, reduced its workforce, and acquired Anelixis Therapeutics on September 14. The combined company is focused on AT-1501, an anti-CD40L antibody, for transplant rejection, autoimmune nephritis, and ALS.
- AT-1501 completed a single-ascending-dose Phase 1 study; the company reported that tested doses were well tolerated, with a safety profile comparable to placebo.
- A Phase 2a ALS study began in October 2020, planned for approximately 54 participants. Health Canada cleared initiation of a Phase 2 islet-cell-transplantation study in November 2020.
Financial results and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $6.1 million | $8.1 million |
| General and administrative expense | $10.1 million | $6.1 million |
| Total operating expenses | $18.5 million | $16.1 million |
| Net loss | $22.8 million | $16.0 million |
| Net loss per share, basic and diluted | $15.72 | $24.42 |
| Net cash used in operating activities | $15.2 million | $13.9 million |
| Cash and cash equivalents at year-end | $114.2 million | $8.8 million |
At December 31, 2020, working capital was $113.1 million and accumulated deficit was $80.4 million. Total liabilities were $6.6 million, including a $4.1 million deferred tax liability and lease liabilities; the filing does not report borrowings as a balance-sheet liability. Cash increased by $105.4 million during 2020, principally reflecting $109.6 million of financing cash inflows and $11.0 million of cash acquired with Anelixis, partly offset by operating cash use. Management stated that available cash was sufficient to meet anticipated needs for at least 12 months from issuance of the financial statements.
Material changes and unusual items
- Net loss increased by $6.8 million year over year. R&D expense fell 25% as legacy ENT development was curtailed; G&A rose 66%, including $2.9 million of Anelixis-related costs and higher public-company and stock-based compensation costs.
- FY2020 included $2.3 million of restructuring expense and $4.8 million of warrant-inducement expense. The latter was a noncash expense associated with repricing warrants and issuing replacement warrants.
- The Anelixis acquisition was accounted for as a business combination. Purchase consideration was $86.8 million; recorded assets included $32.4 million of in-process R&D and $48.6 million of goodwill. The acquired program contributed approximately $2.5 million of net loss from acquisition through year-end.
- Financing included approximately $95.2 million net proceeds from preferred stock, $9.0 million from a common-stock sale, and $5.4 million net proceeds from warrant exercises. The company also effected a 1-for-18 reverse stock split in October. Preferred-stock conversions and other issuances materially increased the share count.
- On March 30, 2021, after year-end, the company entered into an at-the-market agreement permitting sales of up to $75 million of common stock, subject to an effective registration statement; Jefferies’ commission is 3% of gross proceeds.
Outlook, risks, and contingencies
The company expects R&D and G&A spending to increase as it advances AT-1501 and expands its clinical program. It has no formal revenue or earnings guidance and expects continuing losses; management says additional financing will be required to advance development and fund operations over the foreseeable future. Future equity financing could dilute shareholders, while collaboration or licensing arrangements could require relinquishing rights.
- Key risks include failure or delay in clinical trials or regulatory approvals, safety findings, slow enrollment, and the possibility that early-stage results do not predict later outcomes.
- COVID-19 had caused delays in some preclinical work and operational inefficiencies; further effects on trials, suppliers, manufacturing, and access to capital were uncertain.
- The company relies on third parties for clinical testing and manufacturing, has no manufacturing facilities or commercial sales force, and reported no long-term supply agreements or redundant supply arrangements.
- The company reported an ongoing legacy securities lawsuit that was dismissed in October 2020; the appeal was dismissed in February 2021 following an immaterial settlement payment by the company’s insurer. It recorded no contingent liabilities requiring accrual at year-end.
- The auditor issued an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not provide an internal-control attestation.
Important facts for investors to verify
- Current AT-1501 trial status, enrollment, safety findings, and timing of meaningful clinical data—particularly in ALS and islet-cell transplantation.
- Cash burn and actual cash runway against management’s estimate, including expected clinical and manufacturing costs.
- Potential dilution from preferred-stock conversions, outstanding options and warrants, and any use of the $75 million ATM program.
- Acquisition accounting judgments and the carrying value of the $32.4 million IPR&D asset and $48.6 million goodwill.
- Whether legacy ENT assets will be licensed, sold, or otherwise produce value, and any material developments in the company’s licensing, supply, or litigation matters.